Approximately 450 million people worldwide suffer from diabetes, with 90-95% of cases being type 2 diabetes, meaning their bodies have developed resistance to insulin.
Until only recently, the progressive loss of the beta-cells of the pancreas which leads to this metabolic disorder was considered permanent.
Now, thanks to the unique ability of embryonic stem cells to stop auto-immune disorders and trigger repair within all organs of the body, it is possible to reverse the condition and restore all, or part, of the pancreatic functions.
Embryonic stem cells trigger the release of the organ’s own pancreatic stem cells, which become new healthy insulin producing islet clusters within the damaged pancreas.
A study published in the journal of Diabetology & Metabolic Syndrome reported a reduction in insulin resistance following the transplantation of stem cells in mice, and that insulin resistance in diabetes is caused by chronic inflammatory processes. The research confirmed that stem cell therapy can alleviate this inflammation by reprogramming the macrophages to avoid the production of inflammatory chemokines, thus reducing insulin-producing cells and reducing insulin resistance, thereby aiding in the management of type 2 diabetes mellitus.